Human 293 (HEK 293) Cells Market: Immortalized Cell Line for Protein Production & Gene Therapy
公開 2026/04/03 16:06
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Human 293 (HEK 293) Cells - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Human 293 (HEK 293) Cells market, including market size, share, demand, industry development status, and forecasts for the next few years.
For biopharmaceutical researchers, gene therapy developers, and vaccine manufacturers, the need for reliable, easy-to-culture cell lines with high transfection efficiency and compatibility with exogenous gene expression is critical for recombinant protein production, viral vector preparation, and drug screening. The global Human 293 (HEK 293) Cells market addresses this need through an immortalized cell line derived from human embryonic kidney cells via adenovirus type 5 transduction. HEK 293 cells are easy to culture, have high transfection efficiency, and are highly compatible with exogenous gene expression, making them widely used in recombinant protein and monoclonal antibody production, adenoviral and lentiviral vector preparation, gene therapy product development, vaccine development, drug screening, and toxicity testing.
The global market for Human 293 (HEK 293) Cells was estimated to be worth US$ 177 million in 2025 and is projected to reach US$ 307 million, growing at a CAGR of 8.3% from 2026 to 2032. In 2024, global production reached 215,000 vials, with an average selling price of US$ 806 per vial. This growth reflects expanding biopharmaceutical R&D and gene therapy pipelines.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095744/human-293--hek-293--cells
Immortalized Cell Line for Biopharmaceutical Production
HEK 293 cells are an immortalized cell line derived from human embryonic kidney (HEK) cells. They were originally derived through adenovirus type 5 (Ad5) transduction. They are easy to culture, have high transfection efficiency, and are highly compatible with exogenous gene expression. They are widely used in recombinant protein and monoclonal antibody production, adenoviral and lentiviral vector preparation, gene therapy product development, vaccine development, drug screening, and toxicity testing. The "293" designation refers to the cell line derived from the 293rd experiment.
Key advantages include high transfection efficiency (up to 95% with lipid-based reagents), suspension and adherent culture options, and post-translational modification capabilities (human-like glycosylation). The cell line's origin (human) ensures production of properly folded, functional human proteins.
Industry Segmentation: Subtypes & Applications
The Human 293 (HEK 293) Cells market is segmented by cell line variant and end-use application:
HEK293T: Expresses SV40 large T antigen for high-yield plasmid replication. A gene therapy manufacturer reported that HEK293T cells achieved 10x higher lentiviral vector titers compared to standard HEK293.
HEK293E: Enhanced for transient protein expression with EBNA1 gene.
HEK293F: Adapted for serum-free suspension culture for large-scale protein production.
HEK293S: Adapted for growth in suspension with reduced serum requirements.
Others: HEK293-6E and specialized variants for specific applications.
Application Segments
Recombinant Protein Production: Secreted and membrane proteins for research and therapeutic use. A biotech company produced 500 mg/L of monoclonal antibody using HEK293 transient expression.
Gene Therapy: Lentiviral and adenoviral vector production for ex vivo and in vivo gene therapy.
Vaccine Development: Viral vaccine production (adenovirus-vectored vaccines, including COVID-19 vaccines). A vaccine manufacturer used HEK293 cells for adenovirus vector production.
Drug Screening: High-throughput screening assays for drug discovery and toxicity testing.
Others: CRISPR-Cas9 delivery and basic research.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Genome-edited HEK293 cell lines with knockout of specific genes for reduced off-target effects. Enhanced transient expression systems with improved transfection reagents and cell culture media. Serum-free and chemically defined media for regulatory compliance and batch consistency.
The trend toward cell and gene therapy expansion drives demand for HEK293 cells for viral vector manufacturing. COVID-19 vaccine development demonstrated the scalability of HEK293 for adenovirus vector production. CRISPR and gene editing research requires high-efficiency transfection capabilities.
Regional Market Dynamics
North America leads the HEK 293 cells market, driven by strong biopharmaceutical R&D, gene therapy development, and vaccine research. The United States dominates with significant industry and academic research activity.
Europe follows, with strong pharmaceutical and biotechnology sectors in Germany, the UK, and Switzerland. Asia-Pacific is the fastest-growing region, with expanding biopharmaceutical R&D, CRO/CDMO services, and government support in China, Japan, South Korea, and India.
Competitive Landscape
Key players include Altogen Biosystems, ATCC, Synthego, Thermo Fisher Scientific, Beckman Coulter, Sigma Aldrich, Promega, Kerafast, InvivoGen, Innoprot, Takara Bio, BPS Bioscience, ACROBiosystems Group, Porton Pharma Solutions, Ubigene Biosciences, and Wuhan Pricella Biotechnology.
Market Segmentation
The Human 293 (HEK 293) Cells market is segmented as below:
By Company
Altogen Biosystems
ATCC
Synthego
Thermo Fisher Scientific
Beckman Coulter
Sigma Aldrich
Promega
Kerafast
InvivoGen
Innoprot
Takara Bio
BPS Bioscience
ACROBiosystems Group
Porton Pharma Solutions
Ubigene Biosciences
Wuhan Pricella Biotechnology
Segment by Type
HEK293T
HEK293E
HEK293F
HEK293S
Others
Segment by Application
Recombinant Protein Production
Gene Therapy
Vaccine Development
Drug Screening
Others
Exclusive Industry Outlook
Looking ahead, the convergence of HEK 293 cell technology with gene editing, cell therapy, and continuous manufacturing represents a significant growth opportunity. Development of HEK293-derived packaging cell lines for in-house viral vector production. CRISPR-engineered HEK293 cells for stable, high-yield protein expression. Additionally, the expansion of AAV and lentiviral vector manufacturing for gene therapy will drive demand for certified, GMP-grade HEK293 cell banks. The ability to offer Human 293 (HEK 293) cells that combine high transfection efficiency, regulatory compliance, and scalability—supported by cell banking and characterization services—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
For biopharmaceutical researchers, gene therapy developers, and vaccine manufacturers, the need for reliable, easy-to-culture cell lines with high transfection efficiency and compatibility with exogenous gene expression is critical for recombinant protein production, viral vector preparation, and drug screening. The global Human 293 (HEK 293) Cells market addresses this need through an immortalized cell line derived from human embryonic kidney cells via adenovirus type 5 transduction. HEK 293 cells are easy to culture, have high transfection efficiency, and are highly compatible with exogenous gene expression, making them widely used in recombinant protein and monoclonal antibody production, adenoviral and lentiviral vector preparation, gene therapy product development, vaccine development, drug screening, and toxicity testing.
The global market for Human 293 (HEK 293) Cells was estimated to be worth US$ 177 million in 2025 and is projected to reach US$ 307 million, growing at a CAGR of 8.3% from 2026 to 2032. In 2024, global production reached 215,000 vials, with an average selling price of US$ 806 per vial. This growth reflects expanding biopharmaceutical R&D and gene therapy pipelines.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095744/human-293--hek-293--cells
Immortalized Cell Line for Biopharmaceutical Production
HEK 293 cells are an immortalized cell line derived from human embryonic kidney (HEK) cells. They were originally derived through adenovirus type 5 (Ad5) transduction. They are easy to culture, have high transfection efficiency, and are highly compatible with exogenous gene expression. They are widely used in recombinant protein and monoclonal antibody production, adenoviral and lentiviral vector preparation, gene therapy product development, vaccine development, drug screening, and toxicity testing. The "293" designation refers to the cell line derived from the 293rd experiment.
Key advantages include high transfection efficiency (up to 95% with lipid-based reagents), suspension and adherent culture options, and post-translational modification capabilities (human-like glycosylation). The cell line's origin (human) ensures production of properly folded, functional human proteins.
Industry Segmentation: Subtypes & Applications
The Human 293 (HEK 293) Cells market is segmented by cell line variant and end-use application:
HEK293T: Expresses SV40 large T antigen for high-yield plasmid replication. A gene therapy manufacturer reported that HEK293T cells achieved 10x higher lentiviral vector titers compared to standard HEK293.
HEK293E: Enhanced for transient protein expression with EBNA1 gene.
HEK293F: Adapted for serum-free suspension culture for large-scale protein production.
HEK293S: Adapted for growth in suspension with reduced serum requirements.
Others: HEK293-6E and specialized variants for specific applications.
Application Segments
Recombinant Protein Production: Secreted and membrane proteins for research and therapeutic use. A biotech company produced 500 mg/L of monoclonal antibody using HEK293 transient expression.
Gene Therapy: Lentiviral and adenoviral vector production for ex vivo and in vivo gene therapy.
Vaccine Development: Viral vaccine production (adenovirus-vectored vaccines, including COVID-19 vaccines). A vaccine manufacturer used HEK293 cells for adenovirus vector production.
Drug Screening: High-throughput screening assays for drug discovery and toxicity testing.
Others: CRISPR-Cas9 delivery and basic research.
Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Genome-edited HEK293 cell lines with knockout of specific genes for reduced off-target effects. Enhanced transient expression systems with improved transfection reagents and cell culture media. Serum-free and chemically defined media for regulatory compliance and batch consistency.
The trend toward cell and gene therapy expansion drives demand for HEK293 cells for viral vector manufacturing. COVID-19 vaccine development demonstrated the scalability of HEK293 for adenovirus vector production. CRISPR and gene editing research requires high-efficiency transfection capabilities.
Regional Market Dynamics
North America leads the HEK 293 cells market, driven by strong biopharmaceutical R&D, gene therapy development, and vaccine research. The United States dominates with significant industry and academic research activity.
Europe follows, with strong pharmaceutical and biotechnology sectors in Germany, the UK, and Switzerland. Asia-Pacific is the fastest-growing region, with expanding biopharmaceutical R&D, CRO/CDMO services, and government support in China, Japan, South Korea, and India.
Competitive Landscape
Key players include Altogen Biosystems, ATCC, Synthego, Thermo Fisher Scientific, Beckman Coulter, Sigma Aldrich, Promega, Kerafast, InvivoGen, Innoprot, Takara Bio, BPS Bioscience, ACROBiosystems Group, Porton Pharma Solutions, Ubigene Biosciences, and Wuhan Pricella Biotechnology.
Market Segmentation
The Human 293 (HEK 293) Cells market is segmented as below:
By Company
Altogen Biosystems
ATCC
Synthego
Thermo Fisher Scientific
Beckman Coulter
Sigma Aldrich
Promega
Kerafast
InvivoGen
Innoprot
Takara Bio
BPS Bioscience
ACROBiosystems Group
Porton Pharma Solutions
Ubigene Biosciences
Wuhan Pricella Biotechnology
Segment by Type
HEK293T
HEK293E
HEK293F
HEK293S
Others
Segment by Application
Recombinant Protein Production
Gene Therapy
Vaccine Development
Drug Screening
Others
Exclusive Industry Outlook
Looking ahead, the convergence of HEK 293 cell technology with gene editing, cell therapy, and continuous manufacturing represents a significant growth opportunity. Development of HEK293-derived packaging cell lines for in-house viral vector production. CRISPR-engineered HEK293 cells for stable, high-yield protein expression. Additionally, the expansion of AAV and lentiviral vector manufacturing for gene therapy will drive demand for certified, GMP-grade HEK293 cell banks. The ability to offer Human 293 (HEK 293) cells that combine high transfection efficiency, regulatory compliance, and scalability—supported by cell banking and characterization services—will define competitive differentiation.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ